In vivo studies comparing mutant IDH glioma biopsies to wild-type IDH GBM biopsies also showed lower glutamate levels, in spite of the vastly disparate genetic landscape of these tumor types, but trends in other metabolites were more complex 40. This evidence concerns the gene IDH2 and central nervous system cancer.